Rapid Intracranial Response to Zongertinib in HER2-mutated Adenocarcinoma
Figure.An 81-year-old man was diagnosed three years earlier with HER2 exon 20 insertion-mutated lung adenocarcinoma (cT4N3M1c, stage IVB).During chemotherapy, multiple new brain metastases were observed (Picture A and C), accompanied by the complete paralysis of his right upper extremity (manual muscle testing [MMT] grade 0).As a fifth-line therapy, zongertinib was initiated at 120 mg/day three days after the completion of stereotactic radiotherapy for the brain metastases (32.5 Gy in five fractions).His paralysis improved to MMT grade 3 within 12 days, and brain MRI demonstrated
Authors
- Shota Omori (ORCID: https://orcid.org/0000-0003-1407-9779)
- Shuya Miyazaki (ORCID: https://orcid.org/0009-0009-6494-6675)
- Kosaku Komiya (ORCID: https://orcid.org/0000-0002-8679-1661)
- Yuki Kobata
Institutions
- Oita University (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.2169/internalmedicine.8244-26
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00